Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 3/20 | 0.41 |
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3625060 | 0.88 | SLC7A5 (0.47) | CYP2C19ALDH1A1CYP3A4CYP2C9CA12 | |
| SCHEMBL2139709 | 0.86 | ALDH1A1 (0.41) | CYP2C19ALDH1A1CYP3A4CYP2C9CA12 | |
| SCHEMBL13807612 | 0.85 | ALDH1A1 (0.50) | CYP2C19ALDH1A1CYP3A4CYP2C9CA12 | |
| SCHEMBL14090704 | 0.85 | PTPRB (0.40) | CYP2C19ALDH1A1CYP3A4CYP2C9CA12 | |
| SCHEMBL14266632 | 0.84 | ALDH1A1 (0.58) | CYP2C19CYP1A2ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL2139009 | 0.84 | MRGPRX4 (0.46) | CYP2C19ALDH1A1CYP3A4CYP2C9NR1H4 | |
| SCHEMBL5796005 | 0.83 | NQO2 (0.43) | CYP2C19CYP1A2ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL6215165 | 0.83 | ALDH1A1 (0.41) | CYP2C19ALDH1A1CYP3A4CYP2C9CA12 | |
| SCHEMBL3627157 | 0.82 | CTSB (0.51) | CYP2C19ALDH1A1CYP3A4CYP2C9CA12 | |
| SCHEMBL6046380 | 0.82 | PLA2G4B (0.46) | CYP2C19CYP1A2ALDH1A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730103-B1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | PFIZER LTD (GB) | 2010-05-26 | — | — | EP | disclosed |
| EP-1730103-B1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | PFIZER LTD (GB) | 2010-05-26 | — | — | EP | disclosed |
| US-7547731-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547731-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547731-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080207689-A1 | Formamide Derivatives For The Treatment of Diseases | PFIZER INC | 2008-08-28 | — | — | US | disclosed |
| US-20080207689-A1 | Formamide Derivatives For The Treatment of Diseases | PFIZER INC | 2008-08-28 | — | — | US | disclosed |
| US-20080207689-A1 | Formamide Derivatives For The Treatment of Diseases | PFIZER INC | 2008-08-28 | — | — | US | disclosed |
| US-20080193988-A1 | Such as 2-(3-{2-[((2R)-2-{4-Benzyloxy-3-[(dimethylsulfonyl)amino]phenyl}-2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)amino]-2-methylpropyl}phenyl)-N-[(4'-hydroxybiphenyl-3-yl)methyl]-acetamide | GLADWELL IAIN ROBERT | 2008-08-14 | — | — | US | disclosed |
| US-20080193988-A1 | Such as 2-(3-{2-[((2R)-2-{4-Benzyloxy-3-[(dimethylsulfonyl)amino]phenyl}-2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)amino]-2-methylpropyl}phenyl)-N-[(4'-hydroxybiphenyl-3-yl)methyl]-acetamide | GLADWELL IAIN ROBERT | 2008-08-14 | — | — | US | disclosed |
| US-20080193988-A1 | Such as 2-(3-{2-[((2R)-2-{4-Benzyloxy-3-[(dimethylsulfonyl)amino]phenyl}-2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)amino]-2-methylpropyl}phenyl)-N-[(4'-hydroxybiphenyl-3-yl)methyl]-acetamide | GLADWELL IAIN ROBERT | 2008-08-14 | — | — | US | disclosed |
| EP-1907356-A2 | PROCESS FOR THE PREPARATION OF SULFONAMIDE DERIVATIVES | Pfizer Limited (GB) | 2008-04-09 | — | — | EP | disclosed |
| US-7241810-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241810-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241810-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| WO-2007010356-A2 | PROCESS FOR THE PREPARATION OF SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007010356-A2 | PROCESS FOR THE PREPARATION OF SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
| EP-1730103-A1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | Pfizer Limited (GB) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005092840-A1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | PFIZER LIMITED (GB) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207689-A1 | Formamide Derivatives For The Treatment of Diseases | FH, FAH, HRH4 | CYP2C19 163/4885CYP1A2 25/4885ALDH1A1 160/4885 |
| US-20080193988-A1 | Such as 2-(3-{2-[((2R)-2-{4-Benzyloxy-3-[(dimethylsulfonyl)amino]phenyl}-2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)amino]-2-methylpropyl}phenyl)-N-[(4'-hydroxybiphenyl-3-yl)methyl]-acetamide | NR4A1, CYP2A6, GPR6 | CYP2C19 1685/4885CYP1A2 316/4885ALDH1A1 1473/4885 |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | FH, FAH, HRH4 | CYP2C19 163/4885CYP1A2 25/4885ALDH1A1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.